Fig 2: Overall survival rates for (a) patients with tumours harbouring APC/CTNNB1/ZNRF3 alterations in comparison to ones without, (b) overall survival remained significant after removal of patients under 15years of age at the time of operation. (c) Overall survival rates for patients with tumours harbouring CTNNB1 mutations and deletions in comparison to ones without, (d) overall survival in chart c remained significant after removal of patients under 15 years of age at the time of operation.

Fig 3: (a) Western blot results showing expression of wildtype and truncated ß-catenin, Cyclin D1, and Actin in all four samples harbouring deletions in comparison to samples without CTNNB1 mutation or deletion with quantification of Cyclin D1expression. The protein lysate was prepared from the tumours, subjected to SDS page followed by western blot with anti-ß-catenin, anti-Cyclin D1and anti-Actin. Uncropped original blots are shown in Supplementary Fig. 5. (b) mRNA expression of AXIN2, ZNRF3 and LEF1 in tumour samples harbouring APC mutation, CTNNB1 mutation and ?(2 + 3) deletion in comparison to rest of the cohort (p values for AXIN2 and ZNRF3 in ACC wildtype vs APC mutation are 0.1925 and 0.2598 respectively).

Fig 4: Interstitial deletion detected by whole genome sequencing. Eleven reads (dark green) overlapping the deleted region aligned to the reference sequence show deletion from chr3:41218317 to chr3:41224723 spanning over intron 1 to exon 3 of CTNNB1 for sample ACC40.